Last month in the European Society of Cardiology meeting in Barcelona the Deliver trial data was presented, which was also published in NEJM. Dapagliflozin, an SGLT2 inhibitor significantly reduced the composite endpoint of heart failure hospitalisation/ emergency visit for heart failure or cardiovascular morality in more than 6200 patients of heart failure with both mildly reduced or preserved ejection fraction. Adverse effects were similar in the treated and control cohorts, in this large randomised study, follow up was for more than 2 years. Dapagliflozin works in diabetic and non diabetic patients. Dapagliflozin had earlier shown significant improvement in clinical outcomes in patients of heart failure with reduced ejection fraction. Crucially, dapagliflozin is easily available in India at a reasonable rate; dose is 10 mg once a day only.